Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Receivables - Net: 2017-2025

Historic Receivables - Net for Cidara Therapeutics (CDTX) over the last 8 years, with Sep 2025 value amounting to $1.9 million.

  • Cidara Therapeutics' Receivables - Net rose 9.54% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 9.54%. This contributed to the annual value of $1.7 million for FY2024, which is 87.96% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Receivables - Net of $1.9 million as of Q3 2025, which was up 0.11% from $1.9 million recorded in Q2 2025.
  • Cidara Therapeutics' Receivables - Net's 5-year high stood at $26.1 million during Q1 2023, with a 5-year trough of $11,000 in Q1 2021.
  • For the 3-year period, Cidara Therapeutics' Receivables - Net averaged around $6.1 million, with its median value being $2.3 million (2024).
  • Its Receivables - Net has fluctuated over the past 5 years, first slumped by 99.83% in 2021, then soared by 79,745.45% in 2022.
  • Cidara Therapeutics' Receivables - Net (Quarterly) stood at $5.4 million in 2021, then climbed by 8.91% to $5.8 million in 2022, then soared by 141.30% to $14.1 million in 2023, then crashed by 87.96% to $1.7 million in 2024, then rose by 9.54% to $1.9 million in 2025.
  • Its Receivables - Net was $1.9 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.7 million in Q1 2025.